ReviewExpert review of vaccines2021
Development of thermostable vaccine adjuvants.
Review in Expert review of vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.Nature communications · 2023Trial
- The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances.Apoptosis : an international journal on programmed cell death · 2026Review
- Natural Macromolecules as Building Blocks for Microcapsule Formation in Drug Delivery.Pharmaceutics · 2026Review
- A Cryoprotectant-Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoParticles (SMNP).Journal of pharmaceutical sciences · 2025Article
- Review
- Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.Vaccines · 2024Review
- Improved thermal stabilization of VSV-vector with enhanced vacuum drying in pullulan and trehalose-based films.Scientific reports · 2024Article
- Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.Frontiers in immunology · 2024Article
- Practical Considerations for Next-Generation Adjuvant Development and Translation.Pharmaceutics · 2023Review
- Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine.Heliyon · 2023Article
- Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration.Vaccine · 2023Article
- A Comprehensive Review of mRNA Vaccines.International journal of molecular sciences · 2023Review
- KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine.NPJ vaccines · 2022Review
- Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.Frontiers in drug delivery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionThe importance of vaccine thermostability has been discussed in the literature. Nevertheless, the challenge of developing thermostable vaccine adjuvants has sometimes not received appropriate emphasis. Adjuvants comprise an expansive range of particulate and molecular compositions, requiring innovative thermostable formulation and process development approaches. AREAS COVERED: Reports on efforts to develop thermostable adjuvant-containing vaccines have increased in recent years, and substantial progress has been made in enhancing the stability of the major classes of adjuvants. This narrative review summarizes the current status of thermostable vaccine adjuvant development and looks forward to the next potential developments in the field. EXPERT OPINION: As adjuvant-containing vaccines become more widely used, the unique challenges associated with developing thermostable adjuvant formulations merit increased attention. In particular, more focused efforts are needed to translate promising proof-of-concept technologies and formulations into clinical products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.